top of page
​BioFinland Member

BioFinland Member

Vactech Oy

Vactech Oy
Company name

Vactech Oy


Biokatu 8, FI-33520 Tampere


+358-3-447 8111





Contact person

Raimo Harju


Raimo Harju

Main categories

Drug Discovery and Development / Drug Delivery

Last updated

7 February 2019

Company profile

Vactech develops and licenses vaccines and novel technologies for vaccines and diagnostics. Our pipeline includes Type 1 Diabetes vaccine, a vaccine against Asthma and Allergy and a VLP technology platform IMAVAC™ suitable for applications like vaccines, adjuvants, delivery vehicles and diagnostics.

Vactech’s flagship project is a patented enterovirus based preventive Type 1 Diabetes (T1D) vaccine, similar to the widely used enterovirus vaccine against polio. The prevalence of T1D is rapidly increasing. With modest target and penetration parameters the revenue of the vaccine is expected to be more than 5 billion dollars only in US and EU during the first 10 years following the market introduction.

Vactech is a privately owned company which has engaged in a strategic partnership with Provention Bio, Inc. especially in the field of T1D vaccine, see for additional information.

bottom of page